Challenges in Permeability Assessment for Oral Drug Product Development

被引:7
|
作者
Koziolek, Mirko [1 ]
Augustijns, Patrick [2 ]
Berger, Constantin [3 ]
Cristofoletti, Rodrigo [4 ]
Dahlgren, David [5 ]
Keemink, Janneke [6 ]
Matsson, Paer [7 ,8 ]
McCartney, Fiona [9 ]
Metzger, Marco [10 ]
Mezler, Mario [11 ]
Niessen, Janis [5 ]
Polli, James E. [12 ]
Vertzoni, Maria [13 ]
Weitschies, Werner [14 ]
Dressman, Jennifer [15 ]
机构
[1] AbbVie Deutschland GmbH & Co KG, NCE Drug Prod Dev, Dev Sci, D-67061 Ludwigshafen, Germany
[2] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Drug Delivery & Disposit, B-3000 Leuven, Belgium
[3] Univ Hosp Wurzburg, Chair Tissue Engn & Regenerat Med, D-97070 Wurzburg, Germany
[4] Univ Florida, Dept Pharmaceut, 6550 Sanger Rd, Orlando, FL 32827 USA
[5] Uppsala Univ, Dept Pharmaceut Biosci, S-75124 Uppsala, Sweden
[6] F Hoffmann La Roche & Cie AG, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, CH-4070 Basel, Switzerland
[7] Univ Gothenburg, Dept Pharmacol, S-40530 Gothenburg, Sweden
[8] Univ Gothenburg, SciLifeLab Gothenburg, S-40530 Gothenburg, Sweden
[9] Univ Coll Dublin, Sch Vet Med, Dublin D04 V1W8, Ireland
[10] Branch Fraunhofer Inst Silicate Res ISC, Translat Ctr Regenerat Therapies TLZ RT Wurzburg, D-97082 Wurzburg, Germany
[11] AbbVie Deutschland GmbH & Co KG, Quant Translat & ADME Sci, D-67061 Ludwigshafen, Germany
[12] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21021 USA
[13] Natl & Kapodistrian Univ Athens, Dept Pharm, Zografos 15784, Greece
[14] Univ Greifswald, Inst Pharm, D-17489 Greifswald, Germany
[15] Fraunhofer Inst Translat Med & Pharmacol, D-60596 Frankfurt, Germany
基金
瑞典研究理事会;
关键词
permeability; drug absorption; oral drug delivery; in vitro; in silico; in vivo; PASS INTESTINAL PERFUSION; IN-VITRO; STEM-CELLS; GASTROINTESTINAL PH; HUMAN-COLON; DEPENDENT PERMEABILITY; MEMBRANE TRANSPORTERS; COMMON EXCIPIENTS; DELIVERY REVIEWS; DISTAL ILEUM;
D O I
10.3390/pharmaceutics15102397
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed.
引用
收藏
页数:38
相关论文
共 50 条
  • [41] Global harmonization of immediate-release solid oral drug product bioequivalence recommendations and the impact on generic drug development
    Kotsybar, Joseph
    Hakeem, Susan
    Zhang, Lei
    Jiang, Wenlei
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (12): : 2756 - 2764
  • [42] GLOBAL HARMONIZATION OF IMMEDIATE-RELEASE SOLID ORAL DRUG PRODUCT BIOEQUIVALENCE RECOMMENDATIONS AND THE IMPACT ON GENERIC DRUG DEVELOPMENT
    Kotsybar, J.
    Hakeem, S.
    Zhang, L.
    Jiang, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S112 - S112
  • [43] Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration
    Djuris, Jelena
    Cvijic, Sandra
    Djekic, Ljiljana
    PHARMACEUTICALS, 2024, 17 (02)
  • [44] Risk assessment in product development
    Xie Xiaoling
    Hu Xiaoling
    TIRMDCM 2007: PROCEEDINGS OF THE FIRST INTERNATIONAL CONFERENCE ON TECHNOLOGY INNOVATION, RISK MANAGEMENT AND SUPPLY CHAIN MANAGEMENT, VOLS 1 AND 2, 2007, : 282 - 286
  • [45] Environmental assessment in product development
    Alting, L
    Hauschild, M
    Wenzel, H
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES, 1997, 355 (1728): : 1373 - 1386
  • [46] JATENZO®: Challenges in the development of oral testosterone
    Mehul Patel
    Akhil Muthigi
    Ranjith Ramasamy
    International Journal of Impotence Research, 2022, 34 : 721 - 724
  • [47] JATENZO®: Challenges in the development of oral testosterone
    Patel, Mehul
    Muthigi, Akhil
    Ramasamy, Ranjith
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2022, 34 (07) : 721 - 724
  • [48] The drug development pipeline for glioblastoma-A cross sectional assessment of the FDA Orphan Drug Product designation database
    Johann, Pascal
    Lenz, Dominic
    Ries, Markus
    PLOS ONE, 2021, 16 (07):
  • [49] Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five
    Stegemann, Sven
    Moreton, Chris
    Svanbaeck, Sami
    Box, Karl
    Motte, Genevieve
    Paudel, Amrit
    DRUG DISCOVERY TODAY, 2023, 28 (02) : 1 - 13
  • [50] Current challenges for sustainable product development in the German automotive sector: A survey based status assessment
    Held, Maximilian
    Weidmann, Dominik
    Kammerl, Daniel
    Hollauer, Christoph
    Moertl, Markus
    Omer, Mayada
    Lindemann, Udo
    JOURNAL OF CLEANER PRODUCTION, 2018, 195 : 869 - 889